NGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial Results
--Sustained progress across clinical development programs spanning liver, retinal and metabolic diseases and cancer-- --Aldafermin continues to advance toward late-stage clinical development in non-alcoholic steatohepatitis (NASH) with ongoing Phase 2b …